Screening for Biological Response Modifiers: Methods and Rationale / Nejlevnější knihy
Screening for Biological Response Modifiers: Methods and Rationale

Kód: 02180112

Screening for Biological Response Modifiers: Methods and Rationale

Autor James E. Talmadge, Isaiah J. Fidler, R.K. Oldham

The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observat ... celý popis

2357


Skladem u dodavatele
Odesíláme za 5-8 dnů
Přidat mezi přání

Mohlo by se vám také líbit

Darujte tuto knihu ještě dnes
  1. Objednejte knihu a zvolte Zaslat jako dárek.
  2. Obratem obdržíte darovací poukaz na knihu, který můžete ihned předat obdarovanému.
  3. Knihu zašleme na adresu obdarovaného, o nic se nestaráte.

Více informací

Více informací o knize Screening for Biological Response Modifiers: Methods and Rationale

Nákupem získáte 236 bodů

Anotace knihy

The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search for new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for "screening" drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).

Parametry knihy

Zařazení knihy Knihy v angličtině Medicine Clinical & internal medicine Diseases & disorders

2357

Oblíbené z jiného soudku



Osobní odběr Praha, Brno a 46632 dalších

Copyright ©2008-26 nejlevnejsi-knihy.cz Všechna práva vyhrazenaSoukromíCookies


Můj účet: Přihlásit se
Všechny knihy světa na jednom místě. Navíc za skvělé ceny.

Nákupní košík ( prázdný )

Vyzvednutí v Balikovně a PPL
boxech
zdarma nad 1 499 Kč.

Nacházíte se: